Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 5/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15894130 | 1.00 | MAPK1 (0.75) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL15894140 | 1.00 | MAPK1 (0.75) | MAPK1MEN1KMT2ATP53HTT | |
| Hydrochloric Acid SCHEMBL9263619 | 0.99 | MAPK1 (0.73) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL15894143 | 0.99 | MAPK1 (0.77) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL15894133 | 0.95 | KDM4E (0.76) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL17482331 | 0.91 | ALDH1A1 (0.76) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL17482334 | 0.87 | MAPK1 (0.97) | MAPK1MEN1KMT2ATP53HTT | |
| Hydrochloric Acid SCHEMBL9266443 | 0.86 | KMT2A (0.70) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL9260580 | 0.85 | MEN1 (0.72) | MAPK1MEN1KMT2ATP53HTT | |
| SCHEMBL9260326 | 0.85 | MEN1 (0.72) | MAPK1MEN1KMT2ATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031854-A1 | ACTIVATION OR REACTIVATION OF ACHE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014210168-A1 | ACTIVATION OR REACTIVATION OF ACHE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031854-A1 | ACTIVATION OR REACTIVATION OF ACHE | ACHE, BCHE, CHAT | MAPK1 2836/4885MEN1 3198/4885KMT2A 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.